Center for Scientific Review; Notice of Closed Meetings, 64241-64242 [2022-23066]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 204 / Monday, October 24, 2022 / Notices
public is also invited to submit
proposals for additional new core,
developmental, or research objectives
that meet the criteria outlined below.
Healthy People 2030 is the product of
an extensive collaborative process that
relies on input from a diverse array of
individuals and organizations, both
within and outside the federal
government, with a common interest in
improving the nation’s health. Public
comments are a cornerstone of Healthy
People 2030. During the development of
Healthy People 2030, HHS asked for the
public’s comments to help shape the
initiative’s framework (vision, mission,
and overarching goals) and its
objectives. HHS plans to periodically
seek public comment to ensure Healthy
People 2030 remains relevant and
reflects emerging public health issues.
The public now is invited to comment
on one new core objective proposed to
be added to Healthy People 2030. This
new objective was developed by federal
subject matter experts, approved by the
Healthy People Federal Interagency
Workgroup and is presented for the
public’s review and comment. The
objective is:
1. Social Determinants of HealthNEW–07: Increase the proportion of the
voting age citizens who vote. Data
Source: Current Population Survey
(CPS), U.S. Census Bureau and the U.S.
Bureau of Labor Statistics (BLS).
The public is also invited to propose
additional core, developmental, or
research objectives for consideration
that address critical public health
issues. Proposed new objectives must
meet all the objective selection criteria
(see below).
Objective Selection Criteria
Core Objectives
lotter on DSK11XQN23PROD with NOTICES1
Core objectives must meet the
following 5 criteria to be included in
Healthy People 2030. Core objectives
should (1) have a reliable, nationally
representative data source with baseline
data no older than 2015; (2) have at least
2 additional data points beyond the
baseline during the decade; (3) be of
national importance; (4) have effective,
evidence-based interventions available
to achieve the objective; and (5) have
data to help address disparities and
achieve health equity.
Developmental Objectives
Developmental objectives will have
the following characteristics: (1)
represent high priority issues; (2) do not
have reliable baseline data yet; and (3)
have evidence-based interventions
available.
VerDate Sep<11>2014
17:07 Oct 21, 2022
Jkt 259001
Research Objectives
Research objectives will have the
following characteristics: (1) represent
key opportunities to make progress in
areas with limited prior research, a high
health or economic burden, or
significant disparities between
population groups; (2) may or may not
have reliable baseline data; and (3) do
not have evidence-based interventions
available.
Written comments and evidencebased information should be submitted
by email to HP2030Comment@hhs.gov
by 11:59 p.m. ET on December 2, 2022.
Comments received in response to this
notice will be reviewed and considered
by the Healthy People topic area
workgroups, Federal Interagency
Workgroup on Healthy People 2030, and
other federal subject matter experts.
Paul Reed,
RDML, U.S. Public Health Service, Deputy
Assistant Secretary for Health, Office of
Disease Prevention and Health Promotion.
[FR Doc. 2022–22983 Filed 10–21–22; 8:45 am]
BILLING CODE 4150–32–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Digestive Sciences.
Date: November 18, 2022.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ganesan Ramesh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 827–
5467, ganesan.ramesh@nih.gov.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
64241
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Substance
Use, Risks, Mechanisms, and Outcomes.
Date: November 18, 2022.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Izabella Zandberg, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–594–0359,
izabella.zandberg@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neurodegenerative Disorders.
Date: November 18, 2022.
Time: 11:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Roger Alan Bannister,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1010–D,
Bethesda, MD 20892, (301) 435–1042,
bannisterra@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Auditory System, Cognition and
Memory.
Date: November 21, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Pablo Miguel Blazquez
Gamez, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 435–1042,
pablo.blazquezgamez@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–RM–
22–015: IND-enabling Studies of Somatic
Genome Editing Therapeutic Leads.
Date: November 21–22, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Christopher Payne, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 402–3702, christopher.payne@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cell and Molecular Biology.
Date: November 21–22, 2022.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
E:\FR\FM\24OCN1.SGM
24OCN1
64242
Federal Register / Vol. 87, No. 204 / Monday, October 24, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Contact Person: Megan Lynne Goodall,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–8334, megan.goodall@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Drug Discovery and Development.
Date: November 21–22, 2022.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158,
MSC 7806, Bethesda, MD 20892, 301–435–
1180, ruvinser@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Biology of the Eye.
Date: November 21, 2022.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jimok Kim, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6107 Rockledge Drive,
Bethesda, MD 20892, (301) 402–8559,
jimok.kim@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cell Biology, Biochemistry, and
Aging.
Date: November 21, 2022.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kevin Czaplinski, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6901 Rockledge Drive,
Bethesda, MD 20892, (301) 480–9139,
czaplinskik2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 19, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23066 Filed 10–21–22; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:07 Oct 21, 2022
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Early
Detection Research Network: Clinical
Validation Centers (U01) and Biomarker
Characterization Centers (U2C).
Date: November 16, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W260, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Robert F. Gahl, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical
Center Drive, Room 7W260, Rockville,
Maryland 20850, 240–276–7869, robert.gahl@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; A data
resource for blood and marrow transplants
and adoptive cellular therapy research.
Date: November 17, 2022.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W602, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Delia Tang, M.D.,
Scientific Review Officer, Resources Training
and Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W602,
Rockville, Maryland 20850, 240–276–6456,
tangd@mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Cancer
Centers Study Section (A).
Date: December 1–2, 2022.
Time: 10:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
7W530, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Shamala K. Srinivas,
Ph.D., Associate Director, Office of Referral,
Review, and Program Coordination, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W530, Rockville, Maryland 20850,
240–276–6442, ss537t@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: October 19, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23068 Filed 10–21–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
Office of Management and Budget
(OMB) review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, email or call the SAMHSA
Reports Clearance Officer at
carlos.graham@samhsa.hhs.gov or (240)
276–0361.
Proposed Project: Program Evaluation
for Prevention Contract (PEPC)—
Strategic Prevention Framework for
Prescription Drugs (SPF-Rx) Evaluation
(OMB No. 0930–0377)—Revision
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center for Behavioral Health
Statistics and Quality (CBHSQ) aims to
complete a cross-site evaluation of
SAMHSA’s Strategic Prevention
Framework for Prescription Drugs (SPFRx). SPF-Rx is designed to address
nonmedical use of prescription drugs as
well as opioid overdoses by raising
awareness about the dangers of sharing
medications and by working with
pharmaceutical and medical
communities on the risks of
overprescribing. The SPF-Rx program
aims to promote collaboration between
E:\FR\FM\24OCN1.SGM
24OCN1
]]>Agencies
[Federal Register Volume 87, Number 204 (Monday, October 24, 2022)]
[Notices]
[Pages 64241-64242]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23066]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Digestive Sciences.
Date: November 18, 2022.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ganesan Ramesh, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD
20892, (301) 827-5467, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Substance Use, Risks, Mechanisms, and Outcomes.
Date: November 18, 2022.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Izabella Zandberg, Ph.D., Scientific Review
Officer, Center for Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301-594-0359, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Neurodegenerative Disorders.
Date: November 18, 2022.
Time: 11:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Roger Alan Bannister, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1010-D, Bethesda, MD 20892, (301)
435-1042, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Auditory System, Cognition and Memory.
Date: November 21, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Pablo Miguel Blazquez Gamez, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-1042,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA-RM-22-015: IND-enabling Studies of Somatic Genome Editing
Therapeutic Leads.
Date: November 21-22, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Christopher Payne, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 402-3702,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Cell and Molecular Biology.
Date: November 21-22, 2022.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
[[Page 64242]]
Contact Person: Megan Lynne Goodall, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-8334,
[email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Small Business: Drug Discovery and Development.
Date: November 21-22, 2022.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD
20892, 301-435-1180, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Biology of the Eye.
Date: November 21, 2022.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jimok Kim, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6107 Rockledge Drive, Bethesda, MD
20892, (301) 402-8559, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cell Biology, Biochemistry, and Aging.
Date: November 21, 2022.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kevin Czaplinski, Ph.D., Scientific Review
Officer, Center for Scientific Review, 6901 Rockledge Drive,
Bethesda, MD 20892, (301) 480-9139, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: October 19, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-23066 Filed 10-21-22; 8:45 am]
BILLING CODE 4140-01-P
